SCHEMBL6981574

SCHEMBL6981574

COc1cc(C(=O)N2c3ccccc3[C@@H](Nc3ccccc3)C[C@@H]2C)cc(OC)c1OC

nearest known ligand 0.73

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.66
SMN1; SMN2 Q16637 1/20 0.63
GFER P55789 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
P2RY1 P47900 1/20 0.56
PTGDR2 Q9Y5Y4 1/20 0.54
BRD4 O60885 1/20 0.53
BRD2 P25440 1/20 0.53
BRD3 Q15059 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981581 1.00 LMNA (0.66) LMNASMN1; SMN2GFERNPSR1MEN1
SCHEMBL6982599 1.00 LMNA (0.66) LMNASMN1; SMN2GFERNPSR1MEN1
SCHEMBL6982600 1.00 LMNA (0.66) LMNASMN1; SMN2GFERNPSR1MEN1
SCHEMBL6981577 1.00 LMNA (0.66) LMNASMN1; SMN2GFERNPSR1MEN1
SCHEMBL6977893 0.90 LMNA (0.66) LMNASMN1; SMN2GFERNPSR1P2RY1
SCHEMBL6977896 0.90 LMNA (0.66) LMNASMN1; SMN2GFERNPSR1P2RY1
SCHEMBL6977891 0.90 LMNA (0.66) LMNASMN1; SMN2GFERNPSR1P2RY1
SCHEMBL4129242 0.84 LMNA (0.66) LMNASMN1; SMN2GFERNPSR1P2RY1
SCHEMBL4123944 0.84 LMNA (0.66) LMNASMN1; SMN2GFERNPSR1P2RY1
SCHEMBL6418944 0.83 MEN1 (0.64) LMNAMEN1KMT2APTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216398-A1 Soluble beta amyloid precursor protein secretion promoters TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2003-11-20 US disclosed
EP-1283055-A1 SOLUBLE BETA AMYLOID PRECURSOR PROTEIN SECRETION PROMOTERS Takeda Chemical Industries, Ltd. (JP) 2003-02-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216398-A1 Soluble beta amyloid precursor protein secretion promoters APP, BDNF, BACE1 LMNA 1185/4885SMN1; SMN2 149/4885GFER 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.